Yaz (drospirenone & ethinyl/estradiol) is a birth control pill approved in 2001 by the U.S. Food and Drug Administration (FDA) for the prevention of pregnancy. Yasmin is a similar birth control pill first introduced in 2004. The primary difference between Yaz and Yasmin is their chemical make-up
- Yasmin containsf3mg drospirenone and 30mcg ethinyl estradiol
- Yaz contains 3mg drospirenone and 20mcg ethinyl estradiol
A series of Yaz lawsuits have been filed nationwide, and Kogan & Associates is representing women injured after taking Yaz or Yasmin.
Call our firm today to discuss your potential Yaz lawsuit.
These contraceptives have also approved to treat premenstrual dysphoric disorder (PMDD), a condition in which a woman experiences severe depression symptoms, irritability and tension prior to menstruation. PMDD is different from premenstrual syndrome (PMS), which is characterized by a wide range of physical or emotional symptoms five to 11 days prior to the onset of menstruation. PMS symptoms typically stop once a woman’s period begins. Yaz is not approved by the FDA for the treatment of PMS. In addition to preventing pregnancy and treating the symptoms of PMDD, Yaz and Yasmin is also approved for the treatment of moderate acne in women age 14 and over.
Last year, the FDA warned women who were taking Yaz or Yasmin that they were 74 percent more likely to suffer blood clots than women on other low-estrogen contraceptives. Thousands of Yaz lawsuits have been filed, and Kogan & Associates is actively involved with the Yaz litigation.
If you have taken Yaz or Yasmin and have suffered from blood clots (including deep vein thrombosis or pulmonary embolism), or had issues with your gall bladder, call our lawyers immediately to discuss your potential case.
Yaz should not be taken by anyone who smokes and is over the age of 35, as smoking increases the risk of serious life-threatening side effects such as blood clots, stroke and heart attack. In addition, women who have kidney, liver or adrenal disease should also not take Yaz as it can cause serious heart and other health problems. Women who have previously had blood clots, cancers of the breast, ovary or uterus, or who have a history of heart attack or stroke should also not take Yaz.
In clinical trials designed to study the effectiveness of Yaz for contraception and acne treatment, the most common side effects were headache/migraine, menstrual irregularities, nausea/vomiting, breast pain/tenderness, and changes in mood. In the trials designed to study PMDD, the most common side effects include those just listed, as well as fatigue, irritability, decreased libido and weight gain. However, Yaz lawsuits are being filed alleging that Yaz side effects also include deep vein thrombosis, pulmonary embolism and gall bladder disease. Bayer and lawyers representing women allegedly harmed by Yaz are currently discussing Yaz lawsuit settlement amounts.
Call Kogan & Associates immediately
if you have suffered from blood clots or gall bladder problems
since taking Yaz or Yasmin. We can be reached at 800-876-2303.
Bayer Healthcare Pharmaceuticals, Inc. (Bayer), the manufacturer of Yaz, has received two formal warnings from the FDA regarding misleading advertisements to consumers. The first came in October of 2008 when the FDA accused Bayer of misrepresenting the drug’s indications, overstating its efficacy, and minimizing the serious risks associated with its use. As a result, Bayer was forced to discontinue the misleading commercials and launch a $20 million corrective advertising campaign to satisfy the FDA’s concerns and disseminate what the FDA deemed “truthful, non-misleading, and complete corrective messages” to consumers.
A second warning letter came in March of 2009 in response to Bayer’s use of sponsored links on internet search engines such as Google. The FDA found that the links failed to communicate the risks associated with Yaz, did not adequately communicate its approved uses, and did not use its full established name (a requirement under federal law). The FDA again required Bayer to discontinue the misleading advertisements and conduct a full review of promotional materials for all drug products promoted by Bayer in the United States.
Most recently, the FDA has issued a MedWatch Safety Alert regarding drospirenone-containing birth control pills, citing increased concern over the risk of blood clots. A joint meeting between the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee has been scheduled for December 2011, which will likely draw attention back to the serious risks associated with Yaz and other similarly-formulated birth control pills.